Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Target Background
CA9/CAIX (carbonic anhydrase 9) is a zinc metalloenzyme catalyzing the reversible hydration of carbon dioxide. Physiologically, CA9 participates in a variety of biological processes including respiration, calcification, acid-based balance, bone resorption, and the formation of aqueous humor, cerebrospinal fluid, saliva, gastric acid, etc. as a transmembrane protein, and involves in cell proliferation and transformation. With persistent efforts, researchers have revealed that CA9 expression levels associate with various clinicopathological outcomes. For instance, CA9 is now regarded as a cellular biomarker of hypoxia. Furthermore, it is expressed in all clear-cell renal cell carcinoma (ccRCC) and hypoxic solid tumors as one of the only two known tumor-associated carbonic anhydrase isoenzymes, while undetectable in normal kidney and most other normal tissues. Creative Biolabs is able to help researchers to initiate the very first anti-CA9 CAR-T cell therapy.
Anti-CA9 CAR-T Cell Therapy
CA9 has been targeted with multiple monoclonal Abs in clinical trials for the treatment of RCC which have resulted in limited efficiency, and the pilot pre-clinical and clinical CAR-T cell therapy has not yet been reported. Creative Biolabs helps researchers fill in the blank for the cutting-edge immunotherapy.
Animal Models for in vivo Study of anti-CA9 CAR-T Cell Therapy
Creative Biolabs offers researchers almost every particular animal model in the world via the major techniques including the conventional carcinogen-induced models, the mosaic transposon- or virus-induced models, the transgenic models and the subcutaneous or patient-derived xenograft models, and the talented creation of specific requirement to make a stand against RCC.
In vivo Assay Parameters and Techniques
At Creative Biolabs, we offer the most exquisite and comprehensive service platform for preclinical anti-CA9 CAT-T cell therapy research.
Efficacy Test
Tumor remission monitored by tumor volume recording or bioluminescence imaging and survival curve tracking
Viability and Bio-distribution Studies
Durability, bio-distribution studies
Toxicity Evaluation
Pilot tolerability (MTD, The route of administration, Dose regimen/response/onset)
Clinical observation (body weight, feed consumption, ophthalmologic and clinical pathology)
Cytokine storm surveillance (fever, hypertension, prolonged cytopenia)
Complete necropsy, organ weight
Histopathology
Tumorigenicity study
You request, Creative Biolabs offers the best.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
